TB-500 and Thymosin Alpha-1 are supplied strictly as laboratory research materials. They are not approved, intended or authorised for human consumption or any therapeutic use in this context. This article is written for qualified researchers and is not medical advice.
One family name, two different jobs
The word "thymosin" hides a trap. It sounds like a single class of molecule, but it actually spans several unrelated peptide families originally fractionated from thymus tissue decades ago. TB-500 and Thymosin Alpha-1 both inherited the name — and there the resemblance more or less ends. TB-500 is drawn from the beta branch (thymosin beta-4), a cytoskeletal regulator; Thymosin Alpha-1 sits in the alpha branch, an immune signalling peptide. Reading their profiles side by side is a useful reminder that shared nomenclature is not shared mechanism. Here we put the two flagship compounds together.
| TB-500 | Thymosin Alpha-1 | |
|---|---|---|
| Peptide type | Actin-binding repair fragment (thymosin beta-4 domain) | Immunomodulatory thymic peptide |
| Primary mechanism | G-actin sequestration; cell migration | TLR9 / TLR2 activation; T-cell maturation |
| Structure / MW | 7 aa (Ac-LKKTETQ) · ~889 g/mol | 28 aa, N-acetylated · ~3108 Da |
| Half-life / duration | — | ~2 hours |
| Main research focus | Tissue repair, wound healing, angiogenesis | Immune modulation, antiviral, oncology adjunct |
| Regulatory status | Research compound; WADA-prohibited (S0) | Approved as Zadaxin in 35+ countries |
TB-500: the actin-binding repair fragment
TB-500 is a synthetic heptapeptide corresponding to the actin-binding domain of thymosin beta-4 (Tβ4), a 43-amino-acid protein present in virtually all nucleated mammalian cells. Rather than reproduce the whole parent molecule, TB-500 isolates the Ac-LKKTETQ motif — the short sequence responsible for the parent protein's best-characterised activity. At roughly 889 g/mol it is a compact reagent, and its biology is firmly cytoskeletal.
Its primary mechanism is sequestration of globular G-actin monomers. Actin cycles between monomeric G-actin and polymeric F-actin, and the ratio between the two governs how a cell migrates, divides and changes shape. By binding G-actin with high affinity (Kd ~0.7 µM), TB-500 shifts the pool available for polymerisation, influencing the lamellipodia and filopodia that drive directed cell migration. Preclinical work has also linked it to transient upregulation of matrix metalloproteinases (MMP-1, -2, -9), which remodel the extracellular matrix as repair cells move through damaged tissue. The research literature — including the 2003 Philp work on diabetic and aged mice — clusters around wound healing, angiogenesis, and cardiac and corneal repair models. For researchers sourcing material, our page to buy TB-500 UK lists strengths and purity data. Note the regulatory framing: TB-500 is a research compound and is WADA-prohibited under S0 (non-approved substances).
Thymosin Alpha-1: the immune modulator
Thymosin Alpha-1 (Tα1) is a very different animal. It is a 28-amino-acid, N-terminally acetylated peptide first isolated from bovine thymus tissue by Goldstein and colleagues in 1972 and later synthesised. Unlike TB-500, it carries a mature clinical footprint: it is registered as the medicinal product Zadaxin in over 35 countries, with approved indications spanning chronic hepatitis B, hepatitis C and adjunctive vaccine support in immunocompromised patients. Its molecular weight (~3108 Da) is more than three times that of TB-500, and it has a documented half-life of around two hours.
Its research interest is immune restoration, not tissue repair. Thymosin Alpha-1 acts primarily through Toll-like receptors TLR9 and TLR2 on dendritic cells, driving maturation of antigen-presenting cells and a T-helper-1 (Th1) response. In parallel it promotes thymic T-cell maturation — replenishing the precursor pool that declines with age and immunosenescence. Published work documents upregulation of IFN-α, IL-2 and IL-12 alongside enhanced NK-cell cytotoxicity in preclinical assays. The framing throughout is that the peptide enhances immune response rather than blunting it, which is unusual for a molecule with such a long clinical track record. Researchers working in this area can source graded material on our page to buy Thymosin Alpha-1 UK, and the full mechanistic detail lives on the Thymosin Alpha-1 knowledgebase profile.
What the differences mean in a research context
The two compounds barely overlap on paper, and that is the point. TB-500 is a short cytoskeletal fragment whose read-outs are migration assays, wound-gap closure and matrix remodelling. Thymosin Alpha-1 is a larger signalling peptide whose read-outs are cytokine profiles, T-cell counts and antigen-presenting-cell maturation. A researcher choosing between them is not weighing two routes to the same endpoint — they are choosing between two entirely separate experimental questions: repair biology versus immune biology.
The contrast in maturity matters too. Thymosin Alpha-1 carries a multi-decade clinical dataset and formal approval as Zadaxin, so its mechanism and pharmacokinetics — including that ~2-hour half-life — are comparatively well characterised. TB-500's evidence base is preclinical and, importantly, complicated by the parent-versus-fragment distinction: some of the wound-healing activity attributed to the sequence may in fact be carried by its metabolites rather than the intact peptide. In practice, TB-500 is most often studied alongside other repair peptides such as BPC-157, whose angiogenic mechanism is complementary, whereas Thymosin Alpha-1 is typically studied as an adjunct within antiviral or oncology immune-reconstitution models. Same family label, different literatures, different reference points.
The bottom line
TB-500 and Thymosin Alpha-1 share a name and nothing else that counts. One is a compact actin-binding fragment studied for tissue repair and cell migration; the other is an immune-modulating thymic peptide with an approved clinical history studied for T-cell and antiviral function. Pick by the question you are asking, not by the family they happen to share. For research-grade material, see our dedicated pages to buy TB-500 UK and buy Thymosin Alpha-1 UK, each ≥99% purity with a COA.